Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 280

1.

The Impact of Cell-Expansion and Inflammation on The Immune-Biology of Human Adipose Tissue-Derived Mesenchymal Stromal Cells.

Buyl K, Merimi M, Rodrigues RM, Moussa Agha D, Melki R, Vanhaecke T, Bron D, Lewalle P, Meuleman N, Fahmi H, Rogiers V, Lagneaux L, De Kock J, Najar M.

J Clin Med. 2020 Mar 4;9(3). pii: E696. doi: 10.3390/jcm9030696.

2.

Frailty score of older patients with haematological malignancies: unsuspected role of mild cognitive impairment.

Thibaud V, Piron A, Bron D.

Br J Haematol. 2020 Mar 6. doi: 10.1111/bjh.16469. [Epub ahead of print] Review.

PMID:
32141067
3.

Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data.

Roex G, Feys T, Beguin Y, Kerre T, Poiré X, Lewalle P, Vandenberghe P, Bron D, Anguille S.

Pharmaceutics. 2020 Feb 24;12(2). pii: E194. doi: 10.3390/pharmaceutics12020194. Review.

4.

Specific effect of hypobaria on cerebrovascular hypercapnic responses in hypoxia.

Aebi MR, Bourdillon N, Kunz A, Bron D, Millet GP.

Physiol Rep. 2020 Feb;8(4):e14372. doi: 10.14814/phy2.14372.

5.

Cardiovascular and Cerebral Responses During a Vasovagal Reaction Without Syncope.

Aebi MR, Bourdillon N, Meziane HB, Nicol E, Barral J, Millet GP, Bron D.

Front Neurosci. 2019 Dec 10;13:1315. doi: 10.3389/fnins.2019.01315. eCollection 2019.

6.

Significance of TIM3 expression in cancer: From biology to the clinic.

Solinas C, De Silva P, Bron D, Willard-Gallo K, Sangiolo D.

Semin Oncol. 2019 Aug - Oct;46(4-5):372-379. doi: 10.1053/j.seminoncol.2019.08.005. Epub 2019 Nov 6. Review.

PMID:
31733828
7.

Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.

Thieblemont C, Howlett S, Casasnovas RO, Mounier N, Perrot A, Morschhauser F, Fruchart C, Daguindau N, van Eygen K, Obéric L, Bouabdallah R, Pica GM, Nicolas-Virezelier E, Abraham J, Fitoussi O, Snauwaert S, Eisenmann JC, Lionne-Huyghe P, Bron D, Tricot S, Deeren D, Gonzalez H, Costello R, Le Du K, da Silva MG, Grosicki S, Trotman J, Catalano J, Caballero D, Greil R, Cohen AM, Gaulard P, Roulin L, Takeshita K, Casadebaig ML, Tilly H, Coiffier B.

Br J Haematol. 2020 Apr;189(1):84-96. doi: 10.1111/bjh.16300. Epub 2019 Nov 8.

PMID:
31702836
8.

Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

Gagelmann N, Eikema DJ, Koster L, Caillot D, Pioltelli P, Lleonart JB, Reményi P, Blaise D, Schaap N, Trneny M, Passweg J, Porras RP, Cahn JY, Musso M, Poiré X, Fenk R, Itälä-Remes M, Pavone V, Fouillard L, Maertens J, Bron D, Pouli A, Schroyens W, Schönland S, Garderet L, Yakoub-Agha I, Kröger N.

Biol Blood Marrow Transplant. 2019 Nov;25(11):2134-2142. doi: 10.1016/j.bbmt.2019.07.004. Epub 2019 Jul 6.

PMID:
31288095
9.

Aviation Cardiology.

Syburra T, von Wattenwyl R, Bron D, Nicol E.

Eur Heart J. 2019 Jul 1;40(25):1998-2000. doi: 10.1093/eurheartj/ehz418. No abstract available.

PMID:
31259376
10.

Marginal zone lymphomas: second most common lymphomas in older patients.

Bron D, Meuleman N; Eurobloodnet for rare diseases and EHA SWG ‘Aging and Hematology’.

Curr Opin Oncol. 2019 Sep;31(5):386-393. doi: 10.1097/CCO.0000000000000554.

PMID:
31246587
11.

Multicultural approaches of cancer pain.

Crombez P, Bron D, Michiels S.

Curr Opin Oncol. 2019 Jul;31(4):268-274. doi: 10.1097/CCO.0000000000000547. Review.

PMID:
31169591
12.

Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium.

Devos T, Verhoef G, Steel E, Mazure D, Lewalle P, Bron D, Berneman Z, Benghiat FS, Mineur P, Theunissen K, Zachée P, Doyen C, Put N, Lejeune M, Van Eygen K, Havelange V, Reusens M, Pluymers W, Peeters K.

Acta Haematol. 2019;142(4):197-207. doi: 10.1159/000499329. Epub 2019 Jun 4.

PMID:
31163431
13.

Health related quality of life in older patients with solid tumors and prognostic factors for decline.

Decoster L, Quinten C, Kenis C, Flamaing J, Debruyne PR, De Groof I, Focan C, Cornelis F, Verschaeve V, Bachmann C, Bron D, Luce S, Debugne G, den Bulck, Goeminne JC, Baitar A, Geboers K, Petit B, Langenaeken C, Van Rijswijk R, Specenier P, Jerusalem G, Praet JP, Vandenborre K, Lobelle JP, Lycke M, Milisen K, Wildiers H.

J Geriatr Oncol. 2019 Nov;10(6):895-903. doi: 10.1016/j.jgo.2019.03.018. Epub 2019 Apr 18.

PMID:
31005649
14.

Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features.

Porcu M, De Silva P, Solinas C, Battaglia A, Schena M, Scartozzi M, Bron D, Suri JS, Willard-Gallo K, Sangiolo D, Saba L.

Cancers (Basel). 2019 Mar 5;11(3). pii: E305. doi: 10.3390/cancers11030305. Review.

15.

Human CD8+ CD25 + CD127 low regulatory T cells: microRNA signature and impact on TGF-β and IL-10 expression.

Rouas R, Merimi M, Najar M, El Zein N, Fayyad-Kazan M, Berehab M, Agha D, Bron D, Burny A, Rachidi W, Badran B, Lewalle P, Fayyad-Kazan H.

J Cell Physiol. 2019 Aug;234(10):17459-17472. doi: 10.1002/jcp.28367. Epub 2019 Feb 25.

PMID:
30805923
16.

Age-related changes in the BACH2 and PRDM1 genes in lymphocytes from healthy donors and chronic lymphocytic leukemia patients.

Chi VLD, Garaud S, De Silva P, Thibaud V, Stamatopoulos B, Berehad M, Gu-Trantien C, Krayem M, Duvillier H, Lodewyckx JN, Willard-Gallo K, Sibille C, Bron D.

BMC Cancer. 2019 Jan 17;19(1):81. doi: 10.1186/s12885-019-5276-2.

17.

Reciprocal immuno-biological alterations occur during the co-culture of natural killer cells and adipose tissue-derived mesenchymal stromal cells.

Najar M, Fayyad-Kazan M, Merimi M, Meuleman N, Bron D, Fayyad-Kazan H, Lagneaux L.

Cytotechnology. 2019 Feb;71(1):375-388. doi: 10.1007/s10616-019-00294-6. Epub 2019 Jan 10.

18.

Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery.

Quinten C, Kenis C, Decoster L, Debruyne PR, De Groof I, Focan C, Cornelis F, Verschaeve V, Bachmann C, Bron D, Luce S, Debugne G, Van den Bulck H, Goeminne JC, Baitar A, Geboers K, Petit B, Langenaeken C, Van Rijswijk R, Specenier P, Jerusalem G, Praet JP, Vandenborre K, Lycke M, Flamaing J, Milisen K, Lobelle JP, Wildiers H.

Qual Life Res. 2019 Mar;28(3):663-676. doi: 10.1007/s11136-018-2062-6. Epub 2018 Dec 3.

PMID:
30511255
19.

Non-coronary cardiac surgery and percutaneous cardiology procedures in aircrew.

Guettler N, Nicol ED, d'Arcy J, Rienks R, Bron D, Davenport ED, Manen O, Gray G, Syburra T.

Heart. 2019 Jan;105(Suppl 1):s70-s73. doi: 10.1136/heartjnl-2018-313060.

20.

Congenital heart disease in aircrew.

Nicol ED, Manen O, Guettler N, Bron D, Davenport ED, Syburra T, Gray G, d'Arcy J, Rienks R.

Heart. 2019 Jan;105(Suppl 1):s64-s69. doi: 10.1136/heartjnl-2018-313059.

21.

Contemporaneous management of valvular heart disease and aortopathy in aircrew.

D'Arcy JL, Syburra T, Guettler N, Davenport ED, Manen O, Gray G, Rienks R, Bron D, Nicol ED.

Heart. 2019 Jan;105(Suppl 1):s57-s63. doi: 10.1136/heartjnl-2018-313056.

22.

Heart muscle disease management in aircrew.

D'Arcy JL, Manen O, Davenport ED, Syburra T, Rienks R, Guettler N, Bron D, Gray G, Nicol ED.

Heart. 2019 Jan;105(Suppl 1):s50-s56. doi: 10.1136/heartjnl-2018-313058.

23.

Management of cardiac conduction abnormalities and arrhythmia in aircrew.

Guettler N, Bron D, Manen O, Gray G, Syburra T, Rienks R, d'Arcy J, Davenport ED, Nicol ED.

Heart. 2019 Jan;105(Suppl 1):s38-s49. doi: 10.1136/heartjnl-2018-313057.

24.

Management of established coronary artery disease in aircrew with previous myocardial infarction or revascularisation.

Davenport ED, Syburra T, Gray G, Rienks R, Bron D, Manen O, d'Arcy J, Guettler NJ, Nicol ED.

Heart. 2019 Jan;105(Suppl 1):s31-s37. doi: 10.1136/heartjnl-2018-313055.

25.

Management of established coronary artery disease in aircrew without myocardial infarction or revascularisation.

Davenport ED, Gray G, Rienks R, Bron D, Syburra T, d'Arcy JL, Guettler NJ, Manen O, Nicol ED.

Heart. 2019 Jan;105(Suppl 1):s25-s30. doi: 10.1136/heartjnl-2018-313054.

26.

The challenge of asymptomatic coronary artery disease in aircrew; detecting plaque before the accident.

Gray G, Davenport ED, Bron D, Rienks R, d'Arcy J, Guettler N, Manen O, Syburra T, Nicol ED.

Heart. 2019 Jan;105(Suppl 1):s17-s24. doi: 10.1136/heartjnl-2018-313053.

27.

Assessing aeromedical risk: a three-dimensional risk matrix approach.

Gray G, Bron D, Davenport ED, d'Arcy J, Guettler N, Manen O, Syburra T, Rienks R, Nicol ED.

Heart. 2019 Jan;105(Suppl 1):s9-s16. doi: 10.1136/heartjnl-2018-313052.

28.

An introduction to aviation cardiology.

Nicol ED, Rienks R, Gray G, Guettler NJ, Manen O, Syburra T, d'Arcy JL, Bron D, Davenport ED.

Heart. 2019 Jan;105(Suppl 1):s3-s8. doi: 10.1136/heartjnl-2018-313019.

29.

White blood cell counts in a geriatric hospitalized population: A poor diagnostic marker of infection.

Compté N, Dumont L, Bron D, De Breucker S, Praet JP, Bautmans I, Pepersack T.

Exp Gerontol. 2018 Dec;114:87-92. doi: 10.1016/j.exger.2018.11.002. Epub 2018 Nov 6.

PMID:
30412726
30.

[Malignant or benign hyperleukocytosis ?]

Spilleboudt C, Thibaut P, Varlet E, Bron D.

Rev Med Brux. 2018;39(4):291-295. French.

PMID:
30320990
31.

Mesenchymal Stromal Cells and Natural Killer Cells: A Complex Story of Love and Hate.

Najar M, Fayyad-Kazan M, Merimi M, Burny A, Bron D, Fayyad-Kazan H, Meuleman N, Lagneaux L.

Curr Stem Cell Res Ther. 2019;14(1):14-21. doi: 10.2174/1574888X13666180912125736. Review.

PMID:
30207245
32.

Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium.

Kenis C, Decoster L, Flamaing J, Debruyne PR, De Groof I, Focan C, Cornélis F, Verschaeve V, Bachmann C, Bron D, Luce S, Debugne G, Van den Bulck H, Goeminne JC, Schrijvers D, Geboers K, Petit B, Langenaeken C, Van Rijswijk R, Specenier P, Jerusalem G, Praet JP, Vandenborre K, Lobelle JP, Lycke M, Milisen K, Wildiers H.

Ann Oncol. 2018 Sep 1;29(9):1987-1994. doi: 10.1093/annonc/mdy210.

33.

[Diagnostic approach of an IgM monoclonal gammopathy and clinical importance of gene MYD88 L265P mutation].

Cilla N, Vercruyssen M, Ameye L, Paesmans M, de Wind A, Heimann P, Meuleman N, Bron D.

Rev Med Brux. 2018 May 30. doi: 10.30637/2018.17-090. [Epub ahead of print] French.

PMID:
29869471
34.

Are we ready for intercultural cancer care?

Crombez P, Michiels S, Bron D.

Curr Opin Oncol. 2018 Jul;30(4):205-211. doi: 10.1097/CCO.0000000000000449. Review.

PMID:
29846273
35.

Long-term follow-up of 2 patients treated with 90 Y-rituximab radioimmunotherapy for relapse of nodular lymphocyte-predominant Hodgkin lymphoma.

Golstein SC, Muylle K, Vercruyssen M, Spilleboudt C, de Wind A, Bron D.

Eur J Haematol. 2018 Sep;101(3):415-417. doi: 10.1111/ejh.13087. Epub 2018 Jul 4.

PMID:
29719928
36.

Advanced Glycation End-Products-, C-Type Lectin- and Cysteinyl/ Leukotriene-Receptors in Distinct Mesenchymal Stromal Cell Populations: Differential Transcriptional Profiles in Response to Inflammation.

Najar M, Fayyad-Kazan M, Raicevic G, Fayyad-Kazan H, Meuleman N, Bron D, Lagneaux L.

Cell J. 2018 Jul;20(2):250-258. doi: 10.22074/cellj.2018.5104. Epub 2018 Mar 18.

37.

Immunological impact of Wharton's Jelly mesenchymal stromal cells and natural killer cell co-culture.

Najar M, Fayyad-Kazan M, Meuleman N, Bron D, Fayyad-Kazan H, Lagneaux L.

Mol Cell Biochem. 2018 Oct;447(1-2):111-124. doi: 10.1007/s11010-018-3297-9. Epub 2018 Jan 30.

PMID:
29380244
38.

Insights into inflammatory priming of mesenchymal stromal cells: functional biological impacts.

Najar M, Krayem M, Merimi M, Burny A, Meuleman N, Bron D, Raicevic G, Lagneaux L.

Inflamm Res. 2018 Jun;67(6):467-477. doi: 10.1007/s00011-018-1131-1. Epub 2018 Jan 23. Review.

PMID:
29362849
39.

Mesenchymal stromal cells of the bone marrow and natural killer cells: cell interactions and cross modulation.

Najar M, Fayyad-Kazan M, Meuleman N, Bron D, Fayyad-Kazan H, Lagneaux L.

J Cell Commun Signal. 2018 Dec;12(4):673-688. doi: 10.1007/s12079-018-0448-4. Epub 2018 Jan 19.

40.

Immunohematology Mesenchymal Stromal Cell-based Therapy: From Research to Clinic.

Najar M, Krayem M, Meuleman N, Bron D, Hélène B, Lagneaux L.

Appl Immunohistochem Mol Morphol. 2018 Mar;26(3):e26-e43. doi: 10.1097/PAI.0000000000000629. Review.

PMID:
29271793
41.

Immunomodulatory effects of foreskin mesenchymal stromal cells on natural killer cells.

Najar M, Fayyad-Kazan M, Meuleman N, Bron D, Fayyad-Kazan H, Lagneaux L.

J Cell Physiol. 2018 Jul;233(7):5243-5254. doi: 10.1002/jcp.26305. Epub 2018 Jan 19.

PMID:
29194614
42.

The micronome of mesenchymal stromal cells is partially responsive to inflammation.

Fayyad-Kazan H, Fayyad-Kazan M, Merimi M, Meuleman N, Bron D, Lagneaux L, Najar M.

Cell Biol Int. 2018 Feb;42(2):254-260. doi: 10.1002/cbin.10897. Epub 2017 Dec 12.

PMID:
29064609
43.

To fly as a pilot after cardiac surgery.

Syburra T, Nicol E, Mitchell S, Bron D, Rosendahl U, Pepper J.

Eur J Cardiothorac Surg. 2018 Mar 1;53(3):505-511. doi: 10.1093/ejcts/ezx346.

44.

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.

Aftimos P, Rolfo C, Rottey S, Offner F, Bron D, Maerevoet M, Soria JC, Moshir M, Dreier T, Van Rompaey L, Michot JM, Silence K, Hultberg A, Gandini D, de Haard H, Ribrag V, Peeters M, Thibault A, Leupin N, Awada A.

Clin Cancer Res. 2017 Nov 1;23(21):6411-6420. doi: 10.1158/1078-0432.CCR-17-0613. Epub 2017 Aug 1.

45.

Rational therapeutic choice for older patients with lymphoma.

Bron D, Soubeyran P; EHA SWG on ‘Aging, Hematology’.

Curr Opin Oncol. 2017 Sep;29(5):322-327. doi: 10.1097/CCO.0000000000000394. Review.

PMID:
28742622
46.

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.

Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, Verhoef G, Linton K, Thieblemont C, Vitolo U, Hiemeyer F, Giurescu M, Garcia-Vargas J, Gorbatchevsky I, Liu L, Koechert K, Peña C, Neves M, Childs BH, Zinzani PL.

Ann Oncol. 2017 Sep 1;28(9):2169-2178. doi: 10.1093/annonc/mdx289.

47.

Extracellular vesicles of bone marrow stromal cells rescue chronic lymphocytic leukemia B cells from apoptosis, enhance their migration and induce gene expression modifications.

Crompot E, Van Damme M, Pieters K, Vermeersch M, Perez-Morga D, Mineur P, Maerevoet M, Meuleman N, Bron D, Lagneaux L, Stamatopoulos B.

Haematologica. 2017 Sep;102(9):1594-1604. doi: 10.3324/haematol.2016.163337. Epub 2017 Jun 8.

48.

Comparison and immunobiological characterization of retinoic acid inducible gene-I-like receptor expression in mesenchymal stromal cells.

Raicevic G, Najar M, Busser H, Crompot E, Bron D, Toungouz M, Lagneaux L.

Sci Rep. 2017 Jun 6;7(1):2896. doi: 10.1038/s41598-017-02850-6.

49.

Unmet needs in the scientific approach to older patients with lymphoma.

Bron D, Aurer I, André MPE, Bonnet C, Caballero D, Falandry C, Kimby E, Soubeyran P, Zucca E, Bosly A, Coiffier B; European Lymphoma Institute (ELI) Group and the EHA SWG “Aging and Hematology”.

Haematologica. 2017 Jun;102(6):972-975. doi: 10.3324/haematol.2017.167619. Review. No abstract available.

50.

Viral-induced Hemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplant.

Dosin G, Aoun F, El Rassy E, Assi T, Lewalle P, Blanc J, van Velthoven R, Bron D.

Clin Lymphoma Myeloma Leuk. 2017 Jul;17(7):438-442. doi: 10.1016/j.clml.2017.05.013. Epub 2017 May 10.

PMID:
28559150

Supplemental Content

Support Center